![]() |
市场调查报告书
商品编码
1301673
生长激素市场 - 按产品、应用、分销渠道及全球预测,2023-2032年Growth Hormone Market - By Product, Application, Distribution Channel, & Global Forecast, 2023 - 2032 |
到2032年,全球生长激素市场规模将明显扩大。生长激素疗法在儿科病人中的应用不断增加,促进了行业增长。这一人口群体中生长激素疾病的全球负担增加了对生长激素疗法的需求。此外,诊断能力的进步和医护人员意识的提高使人们更早地发现了儿科病人的生长相关疾病,从而能够及时用生长激素疗法进行干预。
此外,在该领域经营的行业参与者正在强调合併和收购战略,以保持其行业地位。2023年6月,美国制药公司Eli Lily And Company宣布有意收购Sigilon,这是一家为急性和慢性疾病患者开发功能治疗的生物制药公司。
整个生长激素市场根据产品、应用、分销渠道和地区进行分类。
基于产品,来自溶剂部分的生长激素行业将在2023年至2032年录得显著的增长。生长激素溶剂的易于管理和与不同配方的兼容性有利于其采用。生长激素溶剂的使用有助于提高患者对治疗方案的依从性。通过简化重组过程和尽量减少注射过程中的不适,病人可能会发现更容易和更方便地坚持他们规定的生长激素治疗。
基于应用,从2023年到2032年,特纳综合征领域的行业份额将以6.5%的年复合增长率增长,这是因为生长激素在解决特纳综合征患者面临的生长和发育挑战方面具有显著疗效。生长激素疗法在改善身高、骨密度、身体成分和整体生活质量方面有明显的好处。随着人们对特纳综合征及其影响有了更多的认识,对生长激素等有效干预措施的需求继续增加,为个人实现最佳生长和充分发挥潜力提供了希望和机会。
基于分销渠道,零售药店部分的行业价值将在2032年之前取得显著收益。各种各样的药物容易获得,增加了病人对零售药店的偏好。此外,这些设施直接向病人提供诊断方案、特殊喂养方案和药物。他们经常提供教育资源和材料,以促进病人的健康和福祉。他们可以提供有关各种健康状况、预防性护理和生活方式调整的信息。
从区域角度看,欧洲生长激素市场规模到2032年将达到17亿美元以上。生长激素缺乏症的发病率激增,增加了欧洲对生长激素疗法的需求。该地区的增长也可归因于不断上升的数字化,加上诺华公司、Ferring B.V.等行业参与者的强大存在,专注于产品创新。
Global Growth Hormone Market size will expand significantly through 2032. Growing applications of growth hormone therapy in pediatric patients are contributing to industry growth. The global burden of growth hormone disorders in this demographic has increased the need for growth hormone therapies. Moreover, the advancements in diagnostic capabilities and rising awareness among healthcare professionals have led to earlier detection of growth-related disorders in pediatric patients, enabling timely intervention with growth hormone therapy.
Furthermore, industry players operating in the field are emphasizing mergers and acquisition strategies to retain their industry standing. In June 2023, Eli Lily And Company, an American pharmaceutical company, announced its intent to acquire Sigilon, a biopharmaceutical company that develops functional cures for patients with acute and chronic disorders.
The overall growth hormone market is classified based on product, application, distribution channel, and region.
Based on the product, the growth hormone industry from the solvent segment will record notable growth from 2023 to 2032. The ease of administration and compatibility of growth hormone solvents with different formulation favors its adoption. The use of growth hormone solvents can contribute to improved patient compliance with treatment regimens. By simplifying the reconstitution process and minimizing discomfort during the injection, patients may find it easier and more convenient to adhere to their prescribed growth hormone therapy.
Based on the application, industry share from the Turner syndrome segment will grow at a 6.5% CAGR from 2023 to 2032 due to the remarkable efficacy of growth hormones in addressing the growth and development challenges faced by individuals with Turner syndrome. Growth hormone therapy depicts notable benefits in improving height, bone density, body composition, and overall quality of life. As more awareness is raised about Turner syndrome and its impact, the need for effective interventions like growth hormones continues to increase, providing hope and opportunities for individuals to achieve optimal growth and reach their full potential.
Based on the distribution channel, industry value from the retail pharmacy segment will register significant gains through 2032. The easy availability of a wide range of medications has increased patient preference for retail pharmacies. Moreover, these facilities offer diagnostic solutions, special feeding solutions, and medications directly to patients. They often offer educational resources and materials to promote patient health and well-being. They may provide information on various health conditions, preventive care, and lifestyle modifications.
From the regional perspective, Europe growth hormone market size will reach over USD 1.7 billion by 2032. The surging prevalence of growth hormone deficiency disorders has increased the demand for growth hormone therapies in Europe. The regional growth can also be attributed to rising digitalization coupled with a robust presence of industry players such as Novartis AG, Ferring B.V., and others, focusing on product innovations.